Participated · Equity · Jul 2026

Xeltis develops implantable vascular and cardiovascular devices based on its Restorex® platform, which uses an advanced polymer implant that transforms into the patient’s own tissue and is gradually absorbed. Its lead product, aXess™, is an implantable blood vessel for hemodialysis vascular access that has received CE Mark approval and is being commercially deployed in Europe. The company is enrolling a US pivotal trial of aXess™ (now >50% enrolled) and is preparing for FDA submission and a US market launch. Xeltis plans to use recent funding to support European commercial rollout, upscale manufacturing and advance its XABG and XPAD clinical programs. Financially, the company raised €50m in 2025 from the European Investment Bank and existing shareholders and added €20.5m in 2026 from new and existing investors to fund its next phase of clinical, regulatory and commercial execution.

Participated · Series A · Jun 2026

Airspeed provides an execution-layer platform for revenue teams that deploys autonomous AI agents to act on commercial context across calls, emails, tickets, and CRM. Its platform automatically updates systems, flags risks, and generates follow-ups across the revenue workflow to help sales teams move deals forward. The company is led by CEO Adam Liska and CTO Devang Agrawal. Airspeed serves 200 customers across 20 countries. Financially, the company has raised a total of $25M after the $20M Series A. It plans to use the newly raised capital to expand operations and accelerate product development.

Participated · Equity · Apr 2026

XO Life develops "Brite," a global meta-platform that consolidates digital product and therapy support so pharma and medtech companies can provide patient information, monitoring and engagement in a single infrastructure. The company emphasizes scalability by enabling many therapies and markets to use one platform instead of separate apps for each medication. XO Life works with more than 40 pharmaceutical companies, including three of the world's top ten, and plans to position Brite as a consolidated offering in early 2025. It intends to invest the new funding in AI capabilities and in processes to simplify and speed pharma onboarding across entire portfolios. XO Life focuses on B2B relationships at the interface of patients, medical professionals and the pharmaceutical industry, where long sales cycles and regulatory requirements are prominent. The company is headquartered in Munich and is using successive funding rounds to move from platform build-out to international scaling across Europe.

Participated · Series B · Mar 2025

Buynomics offers AI-embedded software that simulates real-world shoppers to help enterprises optimise pricing, promotions, and product portfolios. Its platform enables organisations to improve revenue, profitability, and market positioning in real time across channels, product portfolios, and geographies. The company reports its Virtual Shoppers AI drives 2–4% gross profit increases while cutting analysis time by up to 80%. Buynomics is operational in over 25 companies with customers including Danone, Unilever, L'Oréal and Vodafone. Founded in 2018, the company has raised over $46 million to date following a $30 million Series B. The latest funding will be used to support global expansion, particularly into North America, and to further enhance its Virtual Shoppers AI technology. Buynomics provides a SaaS platform that helps enterprise customers make commercial and revenue-management decisions by predicting consumer behavior. The company leverages machine learning and behavioral-economics insights and has developed a Virtual Customer technology that models preferences and buying decisions of large groups. Its technology integrates transaction and survey data to improve precision across pricing, promotions, and product-innovation decisions. Buynomics plans to use new funding to widen its lead in predicting consumer behavior, grow its product and commercial teams, and expand into the US market. The startup has a diverse team of over 50 people representing 17 nationalities and intends to open a US office in Q1 2023. Founded in 2018, the company is headquartered in Cologne, Germany. buynomics has developed a DeepTech, AI-powered SaaS platform that simulates purchase processes to predict how customers will react to price and product-portfolio changes. The software helps companies determine optimal pricing and forecast resulting revenue and profit effects. The startup counts mobile-network operators, insurers and consumer-goods manufacturers among its early customers. buynomics was founded in 2018 by Ingo Reinhardt and Sebastian Baier and is based in Cologne. At the time of the report the team comprised around 10 employees. The company recently attracted external capital in the form of a six-figure investment.

Led · Series A · Oct 2024

Somagenetix was founded in 2019 as a spin-off of the University of Zurich and focuses on curing phagocyte disorders with one-time gene therapies. The company has built a lentiviral gene therapy platform and holds three IP assets. Its lead candidate, SGX-001, is being developed for p47 Chronic Granulomatous Disease, an inherited immunodeficiency that impairs phagocyte function and causes recurrent life‑threatening infections. Preclinical development of the p47‑CGD program is supported by the Wyss Zurich Translational Center. Somagenetix aims to start clinical application of SGX-001 during 2026 and to expand the platform to other phagocyte-related diseases. The company recently closed financing to advance its lead candidate and appointed Dr. Andrin Oswald as CEO to lead the clinical-stage transition.